Associated Papers
Mutation-agnostic RNA interference with engineered replacement rescues Tmc1-related hearing loss.
Iwasa Y et al.
Life Science Alliance, 2023
Prevalence and clinical features of autosomal dominant and recessive TMC1-associated hearing loss.
Nishio SY et al.
Human Genetics, 2022
Preventing autosomal-dominant hearing loss in Bth mice with CRISPR/CasRx-based RNA editing.
Zheng Z et al.
Signal Transduction and Targeted Therapy, 2022
Progress in Gene Editing Tools and Their Potential for Correcting Mutations Underlying Hearing and Vision Loss.
Botto C et al.
Frontiers in Genome Editing, 2021
Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction.
Hastings ML et al.
Hearing Research, 2020
Targeted Allele Suppression Prevents Progressive Hearing Loss in the Mature Murine Model of Human TMC1 Deafness.
Yoshimura H et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy, 2019
Identification of four TMC1 variations in different Chinese families with hereditary hearing loss.
Wang H et al.
Molecular Genetics & Genomic Medicine, 2018
Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.
Gao X et al.
Nature, 2018
Gene Therapy in Mouse Models of Deafness and Balance Dysfunction.
Wang L et al.
Frontiers in Molecular Neuroscience, 2018
RNA Interference Prevents Autosomal-Dominant Hearing Loss.
Shibata SB et al.
American Journal of Human Genetics, 2016
Mutations of TMC1 cause deafness by disrupting mechanoelectrical transduction.
Nakanishi H et al.
Auris, Nasus, Larynx, 2014
Identification of three novel hearing loss mouse strains with mutations in the Tmc1 gene.
Manji SS et al.
The American Journal of Pathology, 2012
Beethoven, a mouse model for dominant, progressive hearing loss DFNA36.
Vreugde S et al.
Nature Genetics, 2002
Select a paper to view details